Safety and effectiveness of 8 weeks of Glecaprevir/Pibrentasvir in challenging HCV patients: Italian data from the CREST study.

<h4>Introduction</h4>Glecaprevir/pibrentasvir (G/P) has demonstrated high rates (>95%) of sustained virologic response at posttreatment Week 12 (SVR12) in treatment-naïve (TN) patients with hepatitis C virus (HCV) infection and compensated cirrhosis (CC). Here, in a key real-world subset of TN Itali...

Descripció completa

Dades bibliogràfiques

Autors principals:	Alessio Aghemo, Marcello Persico, Roberta D'Ambrosio, Massimo Andreoni, Erica Villa, Abhi Bhagat, Valentina Gallinaro, Giuliana Gualberti, Rocco Cosimo Damiano Merolla, Antonio Gasbarrini
Format:	Artigo
Idioma:	Inglês
Publicat:	Public Library of Science (PLoS) 2023-01-01
Col·lecció:	PLoS ONE
Accés en línia:	https://doi.org/10.1371/journal.pone.0280165
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!